Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Reshma Shetty co-founded Ginkgo Bioworks in 2008, a leading organism design company. As President and COO, she has overseen ...

Ginkgo Bioworks (DNA) reported its Q4 2024 earnings with a notable increase in cell engineering revenue but faced a significant ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems Under the $29 million ...

In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...